CytomX Therapeutics (CTMX) Free Cash Flow (2014 - 2026)
CytomX Therapeutics' (CTMX) quarterly Free Cash Flow came in at -$25.5 million in Q1 2026, down 20.73% YoY from -$32.2 million in Q1 2025, and down 8.98% on a QoQ basis from -$23.4 million in Q4 2025.
CytomX Therapeutics (CTMX) Free Cash Flow (2014 - 2026) Analysis & Trends
CytomX Therapeutics (CTMX) has 13 years of Free Cash Flow data on file, last reported at -$25.5 million in Q1 2026.
- Quarterly Free Cash Flow fell 20.73% year-over-year to -$25.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$80.2 million (up 1.65% YoY) and the FY2025 annual result came in at -$75.8 million, up 12.4% from the prior year.
- Free Cash Flow slipped to -$25.5 million in Q1 2026, from -$23.4 million in the prior quarter.
- In the past five years, Free Cash Flow ranged from a high of $9.3 million in Q1 2023 to a low of -$42.0 million in Q1 2022.
- A 5-year average of -$21.0 million and a median of -$21.2 million in 2025 frame the typical range for Free Cash Flow.
- The widest YoY moves for Free Cash Flow: up 122.12% in 2023, down 1262.79% in 2023.
- Tracing CTMX's Free Cash Flow over 5 years: stood at -$1.6 million in 2022, then plunged by 1262.79% to -$21.5 million in 2023, then grew by 6.88% to -$20.0 million in 2024, then slipped by 17.29% to -$23.4 million in 2025, then dropped by 8.98% to -$25.5 million in 2026.
- The last three Free Cash Flow figures came in at -$25.5 million (Q1 2026), -$23.4 million (Q4 2025), and -$15.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -389.61 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 437.80 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 477.44 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 292.04 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -95.09 Mn |
| 10 | CytomX Therapeutics | 732.14 Mn | 401.86 Mn | - | -18.07 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -18.07 Mn |
| Jun 30, 2026 | -18.07 Mn |
| Mar 31, 2026 | -25.55 Mn |
| Mar 31, 2026 | -25.55 Mn |
| Dec 31, 2025 | -23.44 Mn |
| Dec 31, 2025 | -23.44 Mn |
| Sep 30, 2025 | -15.42 Mn |
| Sep 30, 2025 | -15.42 Mn |
| Jun 30, 2025 | -15.78 Mn |
| Jun 30, 2025 | -15.78 Mn |
| Mar 31, 2025 | -21.16 Mn |
| Mar 31, 2025 | -21.16 Mn |
| Dec 31, 2024 | -19.99 Mn |
| Dec 31, 2024 | -19.99 Mn |
| Sep 30, 2024 | -20.75 Mn |
| Sep 30, 2024 | -20.75 Mn |
| Jun 30, 2024 | -19.65 Mn |
| Jun 30, 2024 | -19.65 Mn |
| Mar 31, 2024 | -26.16 Mn |
| Mar 31, 2024 | -26.16 Mn |